RAPID Medicare Coverage Is a Band-Aid on a Bureaucratic Wound

The RAPID Pathway Sounds Fast, But Speed Is Relative

On April 23, 2026, CMS and the FDA unveiled the RAPID coverage pathway for breakthrough devices. The program promises payment within two months of FDA authorization, a sharp drop from the year or more that innovators often wait for a Medicare national coverage determination. That is welcome news for patients with failing hearts, tremors, or chronic wounds who have watched superior tools languish in federal limbo while regulators in Europe and Asia moved faster.

But RAPID is still a permission slip written in Washington. CMS will issue a proposed national coverage determination the same day FDA grants authorization, then wait through a 30-day comment period before finalizing payment. Companies must enroll in the FDA's Total Product Life Cycle Advisory Program or meet other eligibility rules, which means only firms with compliance departments and Capitol Hill contacts need apply. The agencies are not removing gates; they are synchronizing them. That is better than nothing. It is not liberation.

User Fees Punish the Smallest Innovators First

While CMS was polishing RAPID, the FDA published its fiscal year 2026 user-fee schedule with little fanfare. An outsourcing facility classified as a small business now owes $6,829 just to register, while a non-small business pays $20,726, plus a $20,486 reinspection fee if an inspector returns. Medical device makers face their own ladder, with premarket application fees running into the hundreds of thousands of dollars and small-business discounts that still leave a boot on the throat of a startup.

And the fees are only the opening invoice. The National Federation of Independent Business reports that regulatory compliance already consumes roughly $12,000 per worker per year at small firms. Add FDA registration, quality-system audits, and the cost of hiring a regulatory affairs specialist, and a two-person shop with a better insulin pump or wound dressing can be priced out before it sells a single unit. The RAPID pathway does not lower these hurdles. It merely tells well-funded applicants which bureaucratic line to stand in.

The ACCESS Model Doubles Down on Top-Down Care

CMS has also been building its ACCESS Model, a technology-enabled care program first announced in late 2025 with applications due April 1, 2026. The model splits participants into four tracks covering early cardio-kidney-metabolic conditions, advanced cardio-kidney-metabolic disease, chronic musculoskeletal pain, and behavioral health, with payments tied to outcome targets instead of individual services. CMS says this will reward results. What it actually rewards is the ability to navigate a 50-page application and hire consultants who speak CMS.

Direct primary care practices, cash-pay specialists, and small telehealth platforms will struggle to meet the reporting requirements. Large hospital systems and private-equity-backed clinics will absorb the new rules and use them to crowd out independent doctors. That pattern repeats across American medicine. Every time Washington announces a pilot, the incumbents capture it.

Site-Neutral Rules Show the Planning Mindset

CMS finalized its 2026 outpatient prospective payment system rule this spring, raising overall rates by 2.6 percent while expanding site-neutral payment cuts to drug administration services at excepted off-campus hospital departments. The agency says this will save Medicare money by paying the same rate for the same service regardless of where it is performed. That sounds efficient until you realize that the price is still set by a federal formula, not by clinics and patients bargaining in a real market.

Meanwhile, CMS will phase out the inpatient-only list over three years, deciding which procedures hospitals may perform on an outpatient basis. The rule runs hundreds of pages and will spawn dozens of compliance sub-specialties. Every tweak produces a lobbying sprint by hospital associations, device manufacturers, and physician groups. That is how a market dies: not with a single decree, but with 2.6 percent here and an inpatient-only exemption there until entrepreneurs spend more time reading the Federal Register than serving patients.

The Libertarian Prescription Is Permissionless Medicine

RAPID, the ACCESS Model, site-neutral pricing, and user-fee schedules all share the same flaw. They treat medicine as a federal planning board treats steel or grain, with Washington deciding who may produce, where they may sell, and what they may charge. The result is predictable. The United States spends roughly $4.8 trillion on health care, yet patients still wait months for approvals that clerks in Switzerland or Singapore handle in weeks.

A better model starts with the doctor-patient relationship. Let physicians prescribe FDA-authorized devices without a separate CMS coverage determination. Let patients use health savings accounts to buy direct-to-consumer monitors, hearing aids, and insulin pumps. Let small compounders and device shops compete on safety and price instead of on regulatory stamina. Some will fail. That is called learning. The current system fails too, but it fails slowly, expensively, and under layers of paper that no single columnist can fully read. The Alamo Post stands for the idea that a free people can manage their own bodies. It is time Washington believed it.